The state of Iowa currently has 4 active clinical trials seeking participants for Type 1 Diabetes research studies. These trials are conducted in various cities, including Iowa City, Des Moines, Sioux City and Cedar Rapids.
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
NCT06334133
Recruiting
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Diabetes Mellitus, Type 1
Register for Updates
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Type 1 Diabetes, Obesity, Overweight
Register for Updates
Type 1 Diabetes Extension Study
NCT02734277
Recruiting
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for... Read More
Gender:
ALL
Ages:
Between 8 years and 35 years
Trial Updated:
04/09/2025
Locations: University of Iowa Health Care Division of Pediatric Endocrinology, Iowa City, Iowa
Conditions: Type 1 Diabetes Mellitus, T1DM, T1D
Register for Updates
A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes
NCT05018585
Recruiting
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype.
Gender:
ALL
Ages:
Between 12 years and 28 years
Trial Updated:
03/11/2025
Locations: University of Iowa Hospital and Clinics, Iowa City, Iowa
Conditions: Type 1 Diabetes Mellitus
Register for Updates